AdametNext – Future Readiness Partner for Biopharma

AdametNext · Pharma competitive intelligence · Future Readiness Partner for BiopharmaIntelligence for what comes next.

AI-enabled, decision-ready competitive intelligence from a pharma-insider team. We help biopharma CI and brand leaders anticipate competitor moves, avoid strategic blind spots and make decisions that stay relevant from development through commercialization.

7+years partnering with biopharma, since 2019
35+full-time CI specialists
10+clients with preferred-vendor status
~14years’ average senior experience
20+medical congresses covered
Who we are

A pharma-insider CI team, built by former brand and CI leaders

AdametNext is a biopharma competitive intelligence firm. We work as an extension of your CI and brand teams, connecting scientific, clinical, regulatory and commercial signals into one view you can act on.

Founded in 2019 by Virendra Kumar after a career leading CI and brand insights at Bayer, GSK and Novartis. Headquartered in Hyderabad, with teams in the US, UK and Singapore.

Our story and leadership →

Pharma-native judgement

Former brand managers and CI leads interpret every signal in its clinical and commercial context.

Connected evidence

Secondary, primary and congress intelligence, triangulated and confidence-rated.

Governed AI delivery

Three proprietary AI platforms add speed and consistency. Our analysts own every conclusion.

Why it matters

Competitive futures are shaped long before launch

Competitor decisions surface in secondary data 12–24 months after they are made.* By then, the window to respond has narrowed. We help you see those shifts at every stage of the asset.

DISCOVER

Where is the science going?

DEVELOP

Which assets are accelerating?

PROVE

What will define differentiation?

APPROVE

How might the regulatory bar shift?

COMPETE

What will sustain standard of care?

01

What is changing?

02

What could it mean for our asset?

03

What should we prepare for now?

OUR ROLE

We answer all three questions, so leaders anticipate competitive change and make decisions that stay relevant from development through commercialization.

*AdametNext analysis of the lag between competitor decisions and IQVIA data, press releases, publications and abstracts.

Our CI services

Three intelligence engines, one decision-ready view

Organized around your KITs and KIQs, not a fixed information feed. We run the full CI cycle, from the annual plan to the tools that run it.

See all CI services →
ALWAYS-ON

Secondary CI

Maintain strategic visibility

  • Competitor, clinical and regulatory monitoring
  • Alerts, trackers and forward watchpoints
  • Landscapes, earnings and IR analysis
QUESTION-LED

Primary CI

Test the critical unknowns

  • Expert, KOL and stakeholder interviews
  • Hypothesis testing and triangulation
  • Confidence-rated view of competitor intent
EVENT-DRIVEN

Conference Intelligence

Capture inflection points

  • 20+ congresses: ASCO, ESMO, ASH, ESC, ATS
  • Pre-congress KIT/KIQ planning
  • Daily highlights and strategic debrief
Therapy area expertise

Depth across seven core therapy areas

Our analysts bring hands-on experience from the brands and pipelines they have supported, not just the databases they have searched.

Oncology
Immunology
Respiratory
Neurology
Cardio­metabolic
Rare Disease
Vaccines & ID
~14years’ average senior experience, across Novartis, Roche, MSD, Bayer, GSK and global consulting
3proprietary AI platforms, with human-validated insights
Our journey so far

From one founder’s conviction to a trusted CI partner

Built to raise the quality of pharma CI, bringing the inside-out perspective of a former brand and CI leader to every engagement.

2019

AdametNext is founded

Virendra Kumar starts ADN after a decade of client-side CI and brand roles at Bayer, GSK and Novartis.

10+

Clients, preferred vendor

Three global top-20 pharma companies, US biotechs and specialty pharma, across primary and secondary CI.

35+

Specialists, four countries

Hyderabad HQ and Delhi, Short Hills NJ, London and Singapore, plus freelance consultants across EU4, Canada, UAE and Australia.

2026

AI-led CI, community-led growth

Three proprietary AI platforms. SAMANVAY brings together India’s pharma GCC community, and ADN exhibits at Pharma CI USA.

Next

Future readiness at scale

SAMANVAY 2027, deeper AI-enabled CI and new therapy-area franchises.

Where we are

Global coverage, delivered from Hyderabad’s pharma GCC hub

Onshore consultants across major pharma markets, backed by our offshore delivery centre. A hybrid model that works around the clock.

AdametNext global presence map Toronto Short Hills, NJ London EU4 Dubai Delhi Hyderabad (HQ) Singapore Brisbane
AdametNext employees: US, UK, India, SingaporeFreelance consultants: Canada, EU4, UAE, Australia
Offshore delivery centre

Hyderabad, India

An emerging pharma GCC capital

9,000+Novartis experts at its Hyderabad hub, its largest outside Switzerland
4,500+roles planned at Sanofi’s Hyderabad GCC

New pharma GCCs, 2024–26: Eli Lilly · Amgen · BMS · MSD · Regeneron · Lonza

Virendra Kumar, Founder and CEO
Leadership

Led by people who have sat in your seat

“We don’t just tell you what competitors are doing. We help you understand what it means for your business, and prepare for what comes next.”

Virendra Kumar · Founder & CEO

16+ years in pharma CI and brand insights · ex-Novartis Global CI Lead, Respiratory · Supported Ultibro, Enerzair & Atectura Breezhaler and Xolair PFS launches

Meet the leadership team →
AI-led platforms

AI speeds the work. Analysts own every conclusion.

Three proprietary platforms power our engagements: AI-enabled, human-validated and client-controlled.

Explore the platforms →
CI KNOWLEDGE MANAGEMENT

CI plans, KITs/KIQs, governed workflows, alerts and Ask CI search, with continuity across teams and years.

MEDICAL CONFERENCE MANAGEMENT

Coverage planning, live capture, task delegation and AI-enabled session insights, inside your secured IT environment.

LIFE SCIENCES INTELLIGENCE

Curated signals across companies, assets and trials, turned into company-specific implications for your portfolio.

What our clients say

Trusted by global pharma, biotech and specialty companies

3 global top-20 pharma companies, US biotechs, and specialty and biosimilar leaders, across therapy areas and indications.

More client voices →

The shared insights were spot-on.

CI Director · Top 10 Pharma

The attention to detail in finding business implications was commendable.

Oncology CI Lead · Global biopharma
Thought leadership

Frameworks from our foresight practice

Signature white papers on how CI teams protect brand value and compete with clear ethical boundaries.

All thought leadership →
Fresh from LinkedIn

Latest from our LinkedIn

Fresh perspectives from our CI practice and ADN Academy, published on LinkedIn.

Follow AdametNext

Follow AdametNext on LinkedIn

CI frameworks, congress takeaways, events and team news, in your feed every week.

Follow us
Follow us on LinkedIn